<DOC>
	<DOCNO>NCT00920205</DOCNO>
	<brief_summary>The purpose study see safe study drug determine best dose use cancer patient future . The study drug design reduce activity protein know `` heat shock protein 90 '' , `` Hsp90 '' . Hsp90 find every cell human body normally help cell ( body ) cope stressful situation . In certain cancer , however , Hsp90 help cancer cell survive grow . By reduce activity Hsp90 , study drug may slow growth , reduce survival , cancer cell .</brief_summary>
	<brief_title>Safety Study MPC-3100 Cancer Patients Who Have Failed Other Treatments</brief_title>
	<detailed_description>This dose escalation study . As subject participate study tolerate specific dose level , new subject enter give high dose study drug .</detailed_description>
	<criteria>recurrent cancer refractory available systemic therapy 18 year old older predict life expectancy equal great 8 week least 4 week post chemotherapy , immunotherapy , surgery , radiation therapy recover treatment toxicity Karnofsky Performance Status equal great 60 ECOG equal less 2 adequate organ function base hematological , liver , renal function LVEF great low limit normal institution , measure MUGA echocardiography washout period first dose o study drug protocol prohibit medication discontinue pregnant breastfeeding receive anticancer treatment investigational therapy within 28 day prior Cycle 1 Day 1 symptom heart failure equal great Class III ( NYHA criterion ) impair cardiac function clinically significant cardiac disease concurrent treatment medication either markedly induce inhibit CYP3A4 concurrent treatment medication relative risk prolong QT interval induce torsades de pointes treatment discontinue switched different medication prior study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>MPC-3100</keyword>
	<keyword>HSP90 inhibitor</keyword>
	<keyword>oral drug</keyword>
	<keyword>cancer</keyword>
</DOC>